Asymmetric total synthesis of Eupalinilide E Integrifolin and allied Guaianolides

Abstract

In regenerative medicine, the primary goal is control of stem cell fate. Nowadays, the enormous application of hematopoietic stem cells (HSCs) in bone marrow transplants make it in a demanding position, which leads to a short supply of clinically viable HSCs. Unfortunately, there is no defined solution and no approved compound/drug for the purpose. So, there is an urgent need for an additional method for expansion to ensure access to a large-scale and accessible resource of HSPCs for future human health. On the other hand, lung cancer is the most common cancer with high lethality. The most frequent oncogenic mutation in lung cancer is KRAS, for which, however, there remain no clinically approved targeted therapies. Moreover, KRAS mutations make cells significantly less susceptible to chemotherapeutic agents. As a result, patients with cancers possessing KRAS mutations have reduced benefits from adjuvant chemotherapy. newline